Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans

• DOI: 10.1126/scitranslmed.aad2195
• Publication Date: 2016-01-27T19:53:13Z
• Authors: Gissette Reyes-So...; Byoung Moon; Antonio Hernandez...; Marija Dionizovik...; Jhonsua Jimenez; Joseph Obunike; Tiffany Thomas; Colleen Ngai; Nelson Fontanez; Daniel S. Donovan; Wahida Karmally; Stephen Holleran; Rajasekhar Ramakr...; Robert S. Mittleman; Henry N. Ginsberg
• Keywords: Adult; Male; Adolescent; Low density lipoproteins; Oligonucleotides; 610; Lipoproteins, VLDL; Biosynthesis; Mice; Animals; Humans; RNA, Small Interfering; Aged; Apolipoproteins B; Hep G2 Cells; Middle Aged; Oligonucleotides, Antisense; Healthy Volunteers; 3. Good health; Lipoproteins, LDL; Apolipoproteins; Lipoproteins, IDL; Liver; Apolipoprotein B-100; Medicine; Female

Targeting apoB synthesis with mipomersen (KYNAMRO) can be effective for lowering plasma levels of lipoproteins without reducing the secretion VLDL.